<DOC>
	<DOCNO>NCT02960906</DOCNO>
	<brief_summary>Disease Stage : naïve metastatic kidney cancer . A multicenter , randomize , Phase 2 BIOmarker drive trial Nivolumab Ipilimumab VEGFR tKi naïve metastatic Kidney cancer</brief_summary>
	<brief_title>A BIOmarker Driven Trial With Nivolumab Ipilimumab VEGFR tKi Naïve Metastatic Kidney Cancer</brief_title>
	<detailed_description>Research Hypothesis : Molecular group ccrcc define patient respond nivolumab alone , nivolumab combine ipilimumab , VEGFR-TKI ( sunitinib pazopanib ) subject previously untreated metastatic renal cell carcinoma ( mRCC ) . Conditions : - Advanced metastatic RCC : previously untreated metastatic setting . - Frozen tumor sample available molecular group determination . Determination molecular subgroup stratification : IMDC prognostic score ( 0 vs 1−2 v 3−6 ) . Product ( ) : - Nivolumab administer IV 60 minute 3 mg/kg combine ipilimumab administer IV 30 minute 1 mg/kg every 3 week 4 dos follow nivolumab administer IV 60 minute 3 mg/kg every 2 week nivolumab l n e administer IV 60 minute 3 mg/kg every 2 week ( molecular group 1 4 ) , TKI ( molecular group 2 3 ) , pazopanib sunitinib accord investigator 's choice disease progression , unacceptable toxicity reason specify protocol . Exploratory biological assessment : Molecular subgroup ( 1 4 ) define patient base frozen tumor tissue sample freshly condition `` RNA later '' . Further exploratory biological assessment perform order define predictive biomarkers response N+I , N alone C : - Molecular subgroup assess FFPE tumor tissue ( Nanostring RNAseq technology ) compare obtain frozen sample - Pan-immune related gene expression assess FFPE tumor tissue primary tumor /or metastasis biopsy baseline metastasis biopsy progression . - Immune cell infiltrates ( CD3 , CD8 , CD20 ) immunosuppressive marker ( PD-1 , PD-L1 &amp; 2 , LAG-3 , TIM3 , CTLA-4 ) assess immunohistochemistry ( IHC ) primary tumor . - The phenotype peripheral blood lymphocyte ( PBL ) analyze 3 time point ( baseline , early treatment progression ) use inhibition regulatory marker cytokine ( PD-1 , TIM-3 , LAG-3 , Perforine , CTLA-4 , Foxp3… ) - Inflammatory protein analyze plasma baseline 3 time point ( baseline , cycle 2 ( W6 ) progression ) , use ELISA nephelometry . Statistical Considerations : An adaptative design use ensure conclusion make limited number patient molecular group , major constraint study . Sample Size : Approximately 150 patient plan treat . Given expected failure rate molecular grouping le 20 % , 180 patient must include .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Histological confirmation RCC clearcell component Metastatic ( American Joint Committee Cancer [ AJCC ] Stage IV ) RCC No prior systemic therapy mRCC Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤2 Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Frozen tumor sample ( primary tumor and/or metastasis biopsy ) must available received central laboratory ( Cordelier Research Center ) determine molecular group . ( Note : fine needle aspiration [ FNA ] bone metastases sample acceptable submission ) . Molecular group determine prior randomization . Formalinfixed , paraffinembedded ( FFPE ) tumor tissue available biomarker ( gene expression immunohistochemistry ( IHC ) ) analysis . Key Any untreated CNS metastasis . Patients CNS metastasis eligible : asymptomatic , without significant oedema , corticosteroid , eligible radiation therapy/surgery already receive radiation therapy . Prior systemic treatment vascular endothelial growth factor ( VEGF ) VEGF receptortargeted therapy ( include , limited , sunitinib , pazopanib , axitinib , tivozanib , bevacizumab ) except adjuvant set free interval 1 year . Prior treatment antiprogrammed cell death protein 1 ( PD1 ) , antiprogrammed deathligand 1 ( PDL1 ) , antiPDL2 , antiCD137 , anticytotoxic Tlymphocyteassociated protein 4 ( CTLA4 ) antibody , antibody drug specifically target Tcell costimulation checkpoint pathway . Any active recent history know suspect autoimmune disease recent history syndrome require systemic corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication except syndrome would expect recur absence external trigger . Subjects vitiligo type 1 diabetes mellitus residual hypothyroidism due autoimmune thyroiditis require hormone replacement permit enroll . Any condition require systemic treatment corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day prior first dose study drug . Inhaled steroid adrenal replacement steroid dose &gt; 10 mg daily prednisone equivalent permit absence active autoimmune disease . Uncontrolled adrenal insufficiency . Ongoing symptomatic cardiac dysrhythmias , uncontrolled atrial fibrillation , prolongation Fridericia correct QT ( QTcF ) interval define &gt; 450 msec male &gt; 470 msec female , QTcF = QT / 3√RR . Poorly control hypertension ( define systolic blood pressure ( SBP ) &gt; 150 mmHg diastolic blood pressure ( DBP ) &gt; 90 mmHg ) , despite antihypertensive therapy . History follow cardiovascular condition within 12 month enrollment : cardiac angioplasty stenting , myocardial infarction , unstable angina , coronary artery bypass graft surgery , symptomatic peripheral vascular disease , class III IV congestive heart failure , define New York Heart Association . History cerebrovascular accident include transient ischemic attack within past 12 month . History deep vein thrombosis ( DVT ) unless adequately treat low molecular weight heparin . History pulmonary embolism within past 6 month unless stable , asymptomatic , treat low molecular weight heparin least 6 week . Known history COPD ( stage ) . Known history uveitis complaint double vision . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month . Serious , nonhealing wound ulcer . Evidence active bleeding bleeding susceptibility ; medically significant hemorrhage within prior 30 day . Any requirement anticoagulation , except low molecular weight heparin . Prior malignancy active within previous 3 year except locally curable cancer apparently cure , basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ prostate , cervix , breast . Known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) . Any positive test hepatitis B hepatitis C virus indicate acute chronic infection . Known medical condition ( e.g. , condition associate diarrhea acute diverticulitis ) , Investigator 's opinion , would increase risk associate study participation study drug administration , interfere interpretation safety result . Known history hyperesthesia , hypoesthesia , paresthesia , dysesthesia , peripheral motor neuropathy , peripheral sensory , neuropathy , polyneuropathy . Major surgery ( e.g. , nephrectomy ) less 28 day prior first dose study drug . Focal radiation therapy le 14 day prior first dose study drug . Receiving concomitant CYP3A4 inducer strong CYP3A4 inhibitor Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption cabozantinib ( e.g. , malabsorptive disorder , ulcerative disease , uncontrolled nausea , vomit , diarrhea , small bowel resection ) . Any follow laboratory test finding : 1 . WBC &lt; 2,000/mm3 2 . Neutrophils &lt; 1,500/mm3 3 . Platelets &lt; 100,000/mm3 4 . AST ALT &gt; 3 x ULN ( &gt; 5 x ULN liver metastasis present ) 5 . Lipase amylase &gt; 1.5 ULN 6 . Total Bilirubin &gt; 1.5 x ULN ( except subject Gilbert Syndrome , total bilirubin &lt; 3.0 mg/dL ) 7 . Serum creatinine &gt; 1.5 x ULN creatinine clearance &lt; 40 mL/min ( measure calculate CockroftGault formula ) 8 . Proteinuria : patient ≥2+ protein urine dipstick baseline must undergo 24hour urine collection protein &gt; 1.0 g protein patient include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>